Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Garo Pehlevanian

Cardiovascular Disease Los Angeles, CA Medical Doctor

NPI 1417919507 CMS profile 199947

5250 Santa Monica Blvd, Ste 207, Los Angeles, CA 90029

Open in the dashboard

General payments

$6,246

295 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Garo Pehlevanian of Los Angeles, CA is reported in the CMS Open Payments database as having received $6,246 across 295 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 73rd percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $483 18
2024 General $551 23
2023 General $535 26
2022 General $899 42
2021 General $1,642 87
2020 General $946 48
2019 General $1,191 51

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Garo Pehlevanian
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Garo Pehlevanian were reported at $483. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Garo Pehlevanian Cardiovascular Disease median Middle half National median
2019 $1,191 $450 $127–$1,392 $163
2020 $946 $242 $77–$751 $114
2021 $1,642 $335 $101–$1,037 $132
2022 $899 $395 $121–$1,211 $149
2023 $535 $443 $136–$1,283 $160
2024 $551 $450 $136–$1,323 $164
2025 $483 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $1,057 43 payments
  2. Pfizer Inc. $578 22 payments
  3. Lilly USA, LLC $559 25 payments
  4. Amgen Inc. $554 31 payments
  5. Takeda Pharmaceuticals U.S.A., Inc. $389 20 payments
  6. Novartis Pharmaceuticals Corporation $384 21 payments
  7. Ironwood Pharmaceuticals, Inc $332 16 payments
  8. Kowa Pharmaceuticals America, Inc. $291 25 payments
  9. Novo Nordisk Inc $286 13 payments
  10. Amarin Pharma Inc. $242 11 payments
  11. Other $1,574 68 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,131 293 payments
  2. Education $115 2 payments
Products named General payments · program years 2019–2025
  1. FARXIGA $847 37 payments
  2. ELIQUIS Cardiovascular;Metabolic Disease $558 21 payments
  3. Repatha $428 26 payments
  4. TRINTELLIX $322 17 payments
  5. Linzess $308 15 payments
  6. JARDIANCE $301 14 payments
  7. Livalo $291 25 payments
  8. Ozempic $239 11 payments
  9. ELIQUIS Cardiovascular $206 10 payments
  10. Bystolic $196 17 payments
  11. Other $4,066 180 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 150 drugs

Part D claims

11,154

Median for Cardiology: 2,533

Drug cost

$1,986,035

Median for Cardiology: $485,213

Branded share of claims

40.6%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 189 $185,042
Omeprazole-Sodium Bicarbonate Omeprazole/Sodium Bicarbonate Brand 130 $150,275
Namzaric Memantine Hcl/Donepezil Hcl Brand 150 $112,071
Trulicity Dulaglutide Brand 102 $100,779
Linzess Linaclotide Brand 158 $93,657
Myrbetriq Mirabegron Brand 151 $84,583
Eliquis Apixaban Brand 136 $84,271
Vascepa Icosapent Ethyl Brand 199 $78,254
Tradjenta Linagliptin Brand 100 $77,954
Repatha Sureclick Evolocumab Brand 118 $77,414

The 10 drugs with the highest cost, of 150 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 10 billing codes

Paid by Medicare

$162,464

Medicare's payments for the services billed

Medicare patients

340

Average age 76

Services billed

2,550

202 women, 138 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Ischemic heart disease 69%
Diabetes 68%
Depression 62%
Alzheimer's or dementia 49%
COPD 39%
Osteoporosis 39%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 13 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
FARXIGA
  • AstraZeneca Pharmaceuticals LP $149
$149 77 —
REXULTI
  • Otsuka America Pharmaceutical, Inc. $108
$108 — —
MOUNJARO
  • Lilly USA, LLC $48
$48 66 —
ZEPBOUND
  • Lilly USA, LLC $48
$48 — —
LEQVIO
  • Novartis Pharmaceuticals Corporation $44
$44 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 13 in the dashboard with a free account

Records

295 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record